Fate Therapeutics (FATE) Short Interest Ratio & Short Volume $1.12 +0.20 (+21.17%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.11 -0.01 (-0.89%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Fate Therapeutics Short Interest DataFate Therapeutics (FATE) has a short interest of 16.37 million shares, representing 15.13% of the float (the number of shares available for trading by the public). This marks a 12.35% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.0, indicating that it would take 7.0 days of the average trading volume of 2.31 million shares to cover all short positions.Current Short Interest16,370,000 sharesPrevious Short Interest14,570,000 sharesChange Vs. Previous Month+12.35%Dollar Volume Sold Short$12.93 millionShort Interest Ratio7.0 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares114,604,000 sharesShort Percent of Float15.13%Today's Trading Volume1,891,313 sharesAverage Trading Volume2,311,452 sharesToday's Volume Vs. Average82% Short Selling Fate Therapeutics? Sign up to receive the latest short interest report for Fate Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartFATE Short Interest Over TimeFATE Days to Cover Over TimeFATE Percentage of Float Shorted Over Time Remove Ads Fate Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202516,370,000 shares $12.93 million +12.4%15.1%7 $0.79 3/15/202514,570,000 shares $13.72 million +9.3%13.5%5.8 $0.94 2/28/202513,330,000 shares $14.93 million +2.1%12.3%4.8 $1.12 2/15/202513,060,000 shares $18.55 million +1.5%12.1%4.4 $1.42 1/31/202512,870,000 shares $16.73 million +1.3%N/A4.2 $1.30 1/15/202512,700,000 shares $16.76 million +13.4%N/A4.1 $1.32 12/31/202411,200,000 shares $18.48 million -8.1%N/A3.8 $1.65 12/15/202412,190,000 shares $22.31 million +7.4%N/A4.5 $1.83 11/30/202411,350,000 shares $35.98 million +9.2%N/A5 $3.17 11/15/202410,390,000 shares $20.99 million -34.7%N/A5.4 $2.02 Get the Latest News and Ratings for FATE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/31/202415,900,000 shares $37.68 million -1.0%N/A12.6 $2.37 10/15/202416,060,000 shares $48.98 million +13.3%N/A12.2 $3.05 9/30/202414,180,000 shares $49.63 million -5.7%N/A8.8 $3.50 9/15/202415,040,000 shares $60.46 million -0.9%N/A9.2 $4.02 8/31/202415,170,000 shares $55.67 million +8.9%N/A8.1 $3.67 8/15/202413,930,000 shares $47.22 million +0.9%N/A6.8 $3.39 7/31/202413,800,000 shares $73.55 million -32.0%N/A6.1 $5.33 7/15/202420,290,000 shares $78.93 million +2.1%N/A8.3 $3.89 6/30/202419,870,000 shares $65.17 million -6.1%N/A8.5 $3.28 6/15/202421,150,000 shares $76.35 million -5.3%N/A8.7 $3.61 5/31/202422,340,000 shares $82.21 million +7.4%N/A8.8 $3.68 5/15/202420,810,000 shares $88.23 million -6.0%N/A8 $4.24 4/30/202422,140,000 shares $87.45 million +17.0%N/A8.5 $3.95 4/15/202418,920,000 shares $106.71 million +14.7%N/A6.8 $5.64 3/31/202416,490,000 shares $121.04 million +25.3%19.0%5.8 $7.34 3/15/202413,160,000 shares $98.57 million -2.5%15.2%4.6 $7.49 2/29/202413,490,000 shares $95.64 million +1.4%15.6%5.1 $7.09 2/15/202413,310,000 shares $94.23 million +15.9%15.5%5.3 $7.08 1/31/202411,480,000 shares $70.72 million +6.6%12.4%4.7 $6.16 1/15/202410,770,000 shares $49.00 million +2.1%11.6%5.3 $4.55 12/31/202310,550,000 shares $39.46 million -2.1%11.4%5.8 $3.74 12/15/202310,780,000 shares $32.56 million -7.9%11.6%6.3 $3.02 11/30/202311,710,000 shares $29.16 million +0.9%12.6%5.6 $2.49 11/15/202311,610,000 shares $28.79 million -1.6%12.5%5.3 $2.48 10/31/202311,800,000 shares $21.36 million -14.5%12.7%5.2 $1.81 10/15/202313,800,000 shares $23.46 million -7.4%14.9%6.1 $1.70 9/30/202314,900,000 shares $31.59 million -38.7%16.1%6.6 $2.12 9/15/202324,290,000 shares $53.44 million -12.1%26.2%10.7 $2.20 8/31/202327,640,000 shares $69.38 million -2.3%29.8%12.7 $2.51 8/15/202328,290,000 shares $82.89 million +2.4%30.5%13.2 $2.93New “Trump” currency proposed in DC (Ad)According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. When you see what could happen – I think you’ll be excited. 7/31/202327,630,000 shares $114.11 million +7.6%29.9%12.9 $4.13 7/15/202325,670,000 shares $121.42 million -1.0%27.8%11.5 $4.73 6/30/202325,930,000 shares $123.43 million -11.9%28.1%10.6 $4.76 6/15/202329,440,000 shares $171.05 million +1.1%31.9%11.7 $5.81 5/31/202329,120,000 shares $147.06 million 0.0%31.5%11.2 $5.05 5/15/202329,130,000 shares $155.26 million +3.7%31.6%10.8 $5.33 4/30/202328,080,000 shares $170.45 million +4.3%30.7%10.3 $6.07 4/15/202326,920,000 shares $161.79 million -1.5%29.5%9.7 $6.01 3/31/202327,340,000 shares $155.84 million +26.7%30.0%9.1 $5.70 3/15/202321,580,000 shares $119.98 million +15.7%23.6%5.4 $5.56 2/28/202318,660,000 shares $114.20 million +10.7%20.4%5.1 $6.12 2/15/202316,850,000 shares $106.83 million +3.5%18.7%4.9 $6.34 1/31/202316,280,000 shares $97.03 million +5.4%17.8%4.9 $5.96 1/15/202315,450,000 shares $83.43 million -30.8%16.9%4.9 $5.40 12/30/202222,330,000 shares $225.31 million +10.3%24.5%7.8 $10.09 12/15/202220,240,000 shares $287.61 million -4.6%22.2%13.5 $14.21 11/30/202221,220,000 shares $441.80 million -4.1%23.2%16.6 $20.82 11/15/202222,120,000 shares $492.83 million -0.5%24.2%16.8 $22.28 10/31/202222,230,000 shares $465.05 million +2.1%24.4%16.3 $20.92 10/15/202221,780,000 shares $443.44 million +0.7%24.0%16.5 $20.36 9/30/202221,620,000 shares $484.50 million +3.9%23.8%16.5 $22.41 9/15/202220,800,000 shares $562.64 million +2.8%22.9%15 $27.05 8/31/202220,240,000 shares $529.07 million +1.6%22.3%13.6 $26.14 8/15/202219,920,000 shares $718.32 million -5.6%21.9%12.9 $36.06 7/31/202221,100,000 shares $644.18 million -0.6%23.3%13 $30.53 7/15/202221,220,000 shares $672.67 million -3.6%23.4%12.9 $31.70 6/30/202222,010,000 shares $545.41 million +6.8%24.4%13.6 $24.78 6/15/202220,600,000 shares $399.23 million +0.6%36.4%13.1 $19.38 5/31/202220,470,000 shares $472.86 million +14.4%22.6%14.3 $23.10 5/15/202217,900,000 shares $433.54 million +8.2%19.8%12.8 $24.22 4/30/202216,550,000 shares $472.67 million +3.4%18.3%12.9 $28.56 4/15/202216,000,000 shares $604.32 million +3.8%17.8%12.2 $37.77 3/31/202215,420,000 shares $597.83 million -1.7%17.1%11.3 $38.77 3/15/202215,690,000 shares $491.25 million +2.0%17.4%11.5 $31.31 2/28/202215,390,000 shares $531.72 million +11.9%17.1%10.8 $34.55 2/15/202213,760,000 shares $521.23 million +9.6%15.4%10 $37.88 1/31/202212,550,000 shares $520.95 million +7.5%14.0%9.8 $41.51 1/15/202211,670,000 shares $505.08 million +1.6%13.0%9.5 $43.28 12/31/202111,490,000 shares $672.28 million +6.3%12.8%10.2 $58.51 12/15/202110,810,000 shares $590.98 million -0.4%12.0%9.8 $54.67 11/30/202110,850,000 shares $596.86 million +7.0%12.1%11.7 $55.01 11/15/202110,140,000 shares $544.82 million -1.8%11.3%10.9 $53.73 10/29/202110,330,000 shares $555.75 million -3.9%11.6%9.7 $53.80 10/15/202110,750,000 shares $658.33 million -5.7%12.1%10.2 $61.24 9/30/202111,400,000 shares $675.68 million -3.4%12.8%11.4 $59.27 9/15/202111,800,000 shares $784.70 million -1.2%13.2%12 $66.50 8/31/202111,940,000 shares $874.61 million -3.1%13.4%11.6 $73.25 8/13/202112,320,000 shares $1.07 billion +0.8%13.8%12.2 $86.71 7/30/202112,220,000 shares $1.01 billion +5.0%13.7%13 $82.80 7/15/202111,640,000 shares $892.79 million -1.7%13.2%12 $76.70New “Trump” currency proposed in DC (Ad)According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. When you see what could happen – I think you’ll be excited. 6/30/202111,840,000 shares $1.03 billion +0.4%13.4%12.1 $86.79 6/15/202111,790,000 shares $1.02 billion -3.1%13.4%11.4 $86.79 5/28/202112,170,000 shares $932.22 million -6.5%13.8%12 $76.60 5/14/202113,020,000 shares $931.06 million +6.5%N/A12.9 $71.51 4/30/202112,230,000 shares $1.05 billion +1.3%N/A12.2 $85.87 4/15/202112,070,000 shares $1.02 billion +0.1%N/A12.3 $84.73 3/31/202112,060,000 shares $893.53 million +4.3%N/A11.6 $74.09 3/15/202111,560,000 shares $1.09 billion +12.2%N/A11.2 $93.99 2/26/202110,300,000 shares $888.58 million +7.0%N/A8.2 $86.27 2/12/20219,630,000 shares $987.08 million -4.5%N/A8 $102.50 1/29/202110,080,000 shares $916.37 million -0.8%N/A8.7 $90.91 1/15/202110,160,000 shares $1.19 billion -8.0%N/A8.9 $117.40 12/31/202011,040,000 shares $1.03 billion -15.6%N/A9.7 $93.62 12/15/202013,080,000 shares $1.26 billion -9.2%N/A12.2 $96.38 11/30/202014,400,000 shares $834.05 million +0.9%N/A13.2 $57.92 11/15/202014,270,000 shares $720.78 million -0.6%N/A16 $50.51 10/30/202014,350,000 shares $654.79 million -3.6%N/A16.7 $45.63 10/15/202014,880,000 shares $698.76 million +7.1%N/A17.4 $46.96 9/30/202013,900,000 shares $555.58 million +7.6%N/A17.2 $39.97 9/15/202012,920,000 shares $485.28 million +1.9%N/A16.2 $37.56 8/31/202012,680,000 shares $461.55 million +2.6%N/A16.2 $36.40 8/14/202012,360,000 shares $425.31 million +1.4%N/A13.6 $34.41 7/31/202012,190,000 shares $381.18 million -0.6%N/A12.1 $31.27 7/15/202012,260,000 shares $427.51 million -1.0%N/A12 $34.87 6/30/202012,380,000 shares $403.71 million +12.7%N/A11.6 $32.61 6/15/202010,990,000 shares $337.94 million -2.4%N/A9.5 $30.75 5/29/202011,260,000 shares $365.16 million -4.9%N/A9 $32.43 5/15/202011,840,000 shares $336.85 million +1.4%N/A9.7 $28.45 4/30/202011,680,000 shares $319.80 million +0.3%N/A10.4 $27.38 FATE Short Interest - Frequently Asked Questions What is Fate Therapeutics' current short interest? Short interest is the volume of Fate Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 16,370,000 shares of FATE short. 15.13% of Fate Therapeutics' shares are currently sold short. Learn More on Fate Therapeutics' current short interest. What is a good short interest ratio for Fate Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FATE shares currently have a short interest ratio of 7.0. Learn More on Fate Therapeutics's short interest ratio. Which institutional investors are shorting Fate Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fate Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Fate Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.13% of Fate Therapeutics' floating shares are currently sold short. Is Fate Therapeutics' short interest increasing or decreasing? Fate Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,370,000 shares, an increase of 12.4% from the previous total of 14,570,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Fate Therapeutics' short interest compare to its competitors? 15.13% of Fate Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Fate Therapeutics: PureTech Health plc (0.04%), Sage Therapeutics, Inc. (7.71%), Mind Medicine (MindMed) Inc. (15.60%), Keros Therapeutics, Inc. (12.97%), CorMedix Inc. (13.77%), Tyra Biosciences, Inc. (12.19%), Precigen, Inc. (14.72%), Zevra Therapeutics, Inc. (11.04%), Revance Therapeutics, Inc. (4.32%), SIGA Technologies, Inc. (9.87%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Fate Therapeutics stock? Short selling FATE is an investing strategy that aims to generate trading profit from Fate Therapeutics as its price is falling. FATE shares are trading up $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Fate Therapeutics? A short squeeze for Fate Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FATE, which in turn drives the price of the stock up even further. How often is Fate Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FATE, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies PRTC Short Squeeze SAGE Short Squeeze MNMD Short Squeeze KROS Short Squeeze CRMD Short Squeeze TYRA Short Squeeze PGEN Short Squeeze ZVRA Short Squeeze RVNC Short Squeeze SIGA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FATE) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts